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Summary Alterations in the c-myc proto-oncogene in colorectal cancer were studied at the level of RNA
expression, gene amplification and rearrangements. One hundred cases of colorectal cancer, stratified by
Dukes' stage were examined. The level of messenger RNA expression was measured in tumours and matched
normal mucosa from the same patient. Between 5 and 400 fold over-expression was found in 66% of tumours.
Neither the presence nor the level of over-expression correlated with tumour staging. A significant correlation
(P<0.01) was found between over-expression of c-myc in tumours and the presence of synchronous adenomas
elsewhere in the colon. In contrast to other tumours, no rearrangements of the gene were found on Southern
analysis of colorectal cancers. Similarly, amplification of the gene was not found in the cancers examined.
Since the establishment of the National Cancer Registry in
1968, Singapore has seen a steady increase in the incidence of
colorectal cancer, with a standardised rate of 19.9 and 15.7
per 100,000 for males and females for the period 1968-1972
compared with rates of 31 and 26.3 for males and females for
1983-1987, giving an increase in incidence of 55% and 67%
respectively. In terms of number of cases, there has been an
average annual increase of 3.5% since 1968. Colorectal
cancer was the sixth most common cancer at the start of the
Cancer Registry; it ranks second today, and will be the most
common cancer in Singapore by the end of this decade.
Being a small country with a dense population of 3 mil-
lion, Singapore provides an ideal opportunity for studying
the carcinogenic process of colorectal cancer, particularly,
because it has three different races which manifest different
risks. Among Singaporeans the incidence of colorectal cancer
is highest in the Chinese population (which comprises 75% of
the total). The Chinese also have the highest rate of increase.
As most of the Chinese population originated from the
Southern coastal provinces of China, any study here will
provide an opportunity for comparing the aetiology of colo-
rectal cancer for Chinese populations in China, Hawaii and
California.
In western populations colorectal cancer is one of the most
intensively studied malignancies, due to the availability of
clearly defined stages between normal colonic mucosa and
the fully malignant carcinoma, and which are now being
correlated to specific gene changes (Fearon & Vogelstein,
1990; Fearon & Jones, 1992). A number of cellular proto-
oncogenes have been examined in colorectal cancer, partic-
ularly the involvement of the cellular proto-oncogene
c-Ki-ras (Burmer et al., 1990; Forrester et al., 1987; Bos et
al., 1987; Vogelstein et al., 1988; Burmer & Loeb, 1989; and
reviewed in Barbacid, 1987; Bos, 1989; Grand & Owens,
1991), and the tumour suppressor gene p53 (Baker et al.,
1990; Rodriguez et al., 1990; Fearon & Vogelstein, 1990;
Baker et al., 1989; Nigro et al., 1989; Hollstein et al., 1991).
Less well studied in colorectal cancer is the proto-oncogene
c-myc, although- this has been intensively studied in other
malignancies such as Burkitts lymphoma (Taub et al., 1982;
Rabbitts et al., 1984; Leder et al., 1983; Dalla Favera et al.,
1982a; Dalla Favera et al., 1983; Eick et al., 1985; Rabbitts et
al., 1983; Hamelyn & Rabbitts, 1983).
The role of c-myc in colorectal carcinomas is not well
understood. Immunohistochemistry has shown that c-myc
gene product in normal colonic tissue is located in the mid
zone of the colonic crypts, which corresponds to the zone of
maturation and differentiation of colonic epithelial cells
(Stewart et al., 1986; Melhem et al., 1992). In adenomas this
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localisation extends into the proliferative zone while in colo-
rectal carcinoma c-myc staining can be found in the mature
zone as well as the maturation and proliferative zones of
colonic crypts (Stewart et al., 1986; Melhem et al., 1992).
Over-expression of the c-myc mRNA has been reported to
occur in between 60%-80% (Finley et al., 1989; Sikora et
al., 1987; Rothberg et al., 1985; Calabretta et al., 1985;
Erisman et al., 1985; Tsuboi et al., 1987; Imaseki et al., 1989)
of colon carcinomas, although the number of samples in
these studies is rather small, from a minimum of six tumours
(Calabretta et al., 1985) to a maximum of 38 (Erisman et al.,
1985; Rothberg et al., 1985). One study by Rothberg et al.
(Rothberg et al., 1985) reports a correlation between over-
expression of c-myc and the location of the tumour, and
although statistically significant, is based on a relatively small
sample size of 38 tumours. However this result has not been
supported by other workers (Imaseki et al., 1989), but again
this is based on a small sample size (11 tumours). As yet no
correlation has been found between over-expression of the
c-myc proto-oncogene and either patient survival or disease
recurrence (Erisman et al., 1988), or metastatic potential
(Tsuboi et al., 1987).
Amplification of the c-myc oncogene has been reported in
fresh colonic tumours, although the incidence is low varying
from 6%, (2/32; Yokota et al., 1986 and 3/45; Meltzer et al.,
1987), to 22% (2/9; Alexander et al., 1986). A better correla-
tion is found when only aggressive subtypes of colorectal
tumours (such as mucinous or poorly differentiated tumours)
were examined. In these cases slight amplification of the
c-myc gene is found in approximately 50% of cases (Heerdt
et al., 1991). None of these papers report any rearrangement
of the c-myc gene in colorectal carcinomas.
The present study was undertaken with two main points in
mind. Firstly we wished to examine the type of oncogenic
changes occurring in an Asian population which is showing a
rapid increase in incidence of colorectal cancer. Secondly we
wished to determine, using a larger sample base, accurate
correlations between c-myc and various clinical correlates
such as Dukes' stage, age, sex, and tumour site.
Materials and methods
Tumour specimens
Samples used in this study were from patients admitted to
the Department of Colorectal Surgery at Singapore General
Hospital. No initial chemotherapy, radiotherapy or hormonal
therapy was given prior to tumour excision. A portion of the
surgically removed tumour was snap frozen in liquid nitrogen
and stored at - 80°C until required. The remainder of the
tumour sample was sent for histopathological diagnosis.
Control mucosa (sited at least 10 cm proximal to the site of
the tumour) was also removed and similarly treated.
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Isolation ofRNA and Northern blotting
RNA was extracted from tumour and mucosa samples by
the method of Chomcznski and Sacchi (Chomcznski & Sac-
chi, 1987), followed by caesium chloride centrifugation
(Sambrook et al., 1989) and quantitated by UV spec-
trophotometry. Total RNA was fractionated through for-
maldehyde-agarose gels, transferred to a solid matrix
(Hybond-N, Amersham, Arlington Heights, IL), and hybrid-
ised to 32P random primed labelled (Feinberg & Vogelstein,
1983; 1984) cDNA probes. The following double-stranded
probes were employed: c-myc cDNA (pGl-5'-c-myc; Amer-
ican Type Culture Collection, Rockville, MD); P-actin cDNA
clone (Clontech Laboratories, Palo Alto, CA). After hyb-
ridisation filters were exposed to Fuji-RX medical X-ray film
(Japan) for between 2-5 days. Signal was quantitated on a
CS-9000 scanning densitometer (Shimadzu, Japan). Corrected
myc signal in the tumour was compared to the corrected myc
signal in the mucosa by comparison with the 13-actin control
signal to obtain a number representing the level of over-
expression in the tumour. Reproducibility was assessed by
10% of the samples being analysed on separate Northern
filters. Reproducibility for all samples was found to be
± 30%, with the majority being ± 20%. The greatest
variation was found in one sample from which RNA was
extracted from two separate portions of the tumour and
probably reflects differing amounts of stromal cell con-
tamination.
Isolation ofDNA, Southern hybridisation and DNA dot blot
analysis
DNA was isolated by standard methods (Davis et al., 1986).
For dot blot analysis approximately 10 gg of genomic DNA
was transferred to a Nylon filter (Hybond-N, Amersham),
denatured by soaking in 1.5 M NaCl, 0.5 M NaOH and neut-
ralised by soaking in 2 M NaCl, 0.5 M Tris-HCl pH 6.0. After
drying, DNA was cross-linked by UV radiation and filter
hybridised overnight to random prime (Feinberg & Vogel-
stein, 1983; 1984) labelled cDNA probes. Probes used were
c-myc exon 1 cDNA (pGl-5'-c-myc; American Type Culture
Collection, Rockville, MD); carboxypeptidase H (Manser et
al., 1990); c-Ki-ras exon 1 (Barbacid, 1987) PCR (Saiki et al.,
1988; Mullis & Faloona, 1987; Saiki et al., 1985) product
(primers from Clontech Laboratories, Palo Alto, CA) and
P-actin (Clontech Laboratories, Palo Alto, CA). After each
exposure the filter was stripped by boiling in 0.1% SDS. For
Southern analysis 10 tig of normal mucosa and tumour DNA
was digested with EcoRl restriction endonuclease (New Eng-
land Biolabs) and subjected to electrophoresis on a 0.8%
agarose gel. After electrophoresis, DNA was denatured and
neutralised as above and transferred to solid matrix
(Hybond-N, Amersham) by overnight capillary action. The
filter was hybridised overnight with c-myc cDNA probe
(pGl-5'-c-myc; American type Culture Collection, Rockville,
MD), labelled by the random prime method (Feinberg &
Vogelstein, 1983; 1984) with 32P, and autoradiography per-
formed.
Results
Over-expression of c-myc RNA
The level of c-myc messenger RNA in 100 colorectal tumours,
equally divided by Dukes' stage (25 Dukes' A, 25 Dukes' B,
25 Dukes' C and 25 Dukes' D) was measured and compared
to levels found in normal mucosa from the same patient. The
tumours came from 55 male and 45 female patients, average
age 62 years (range 24-89 years). There were 92 Chinese
patients and eight others. In each case, 10 fig of total RNA
from both the tumour and from matched normal mucosa
was fractionated through formaldehyde-agarose gels and
hybridised initially with c-myc cDNA. To compensate for
variations in the amount of RNA loaded in each lane a
second hybridisation with ,-actin was undertaken. Levels of
c-myc were then quantitated against levels of P-actin. In all
66 of the tumours were shown to over-express c-myc (see
Figure 1). Only tumours showing a greater than 3-fold in-
crease in c-myc levels were considered to be over-expressing.
Thirty-four per cent of the tumours showed no over-
expression. Low levels of over-expression (3-10-fold increase
in levels of c-myc RNA) was found in 20%, moderate levels
of c-myc over-expression (11-30-fold increase) was found in
29%, and high levels of RNA over-expression (>30-fold
increase) was found in 17% (see Table I) of tumours. No
correlation was found between the presence of c-myc over-
expression and the stage of the tumour (see Table II); the
level of c-myc over-expression and Dukes' staging (see Table
III); the presence of c-myc over-expression and age (Table
IV) or sex (Table V).
Furthermore in contrast to other workers (Rothberg et al.,
1985), no correlation was found between the site of the
tumour, i.e. left or right side tumours (where left side
tumours are those of the rectum, sigmoid colon, descending
colon and splenic flexure and right side tumours are those of
the caecum, hepatic flexure, ascending colon and transverse
colon) and c-myc over-expression (see Table VI). c-myc over-
expression did however correlate with the presence of syn-
chronous adenomas (Table VII). Of the 66 patients where
over-expression was found in the tumour, 22 possessed syn-
chronous polyps, while only two patients out of 34 not
having c-myc over-expression also possessed synchronous
polyps. Hence there is a significant correlation (P>0.01,
analysed by x2 test) between tumours over-expressing c-myc
and the presence of synchronous polyps. Five patients had
synchronous cancers and tumours from four out of the five
Table I Levels of c-myc expression in colorectal carcinomas
Nil Low Medium High
Fold (3-10) (11-30) (31+)
Amplification
All tumours 34 20 29 17
Table II Over-expression of c-myc stratified by Dukes' stage
Dukes' Over Non-over
stage expressing expressing
A 20 (80%) 5 (20%)
B 18 (72%) 7 (28%)
C 13 (52%) 12 (48%)
D 15 (60%) 10 (40%)
Table III Degree of over-expression of c-myc stratified by Dukes'
stage
Dukes' 0-3 4-9 10-30 31+
stage Nil Low Moderate High
A 5% 2% 13% 5%
B 7% 8% 6% 4%
C 12% 4% 5% 4%
D 10% 6% 5% 4%
Table IV Over-expression of c-myc stratified by age
Number oftumours %
Non-over Over
Age Over expressing expressing expressing
20-29 1 1 50
30-39 1 1 50
40-49 11 3 78
50-59 17 5 77
60-69 19 12 61
70-79 13 9 59
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Table V Over-expression of c-myc stratified by sex
Number oftumours %
Non-over Over
Over expressing expressing expressing
Male 33 22 60
Female 33 12 73
Table VI Over-expression of c-myc stratified by tumour location
Number oftumours %
Non-over Over
Over expressing expressing expressing
Left 52 28 65
side
Right 9 6 60
side
Table VII Correlation of presence of synchronous adenomas with
over-expression of c-myc
Patients Patients
with polyps without polyps
Tumours over 22 44
expressing
Tumours non-over 2 32
expressing
the tumour and 10fig of DNA from matched normal mucosa
of the same patient was digested with the restriction
endonuclease Eco RI, the digest products were separated on
a 0.8% agarose gel and then transferred to solid nylon
matrix support prior to hybridisation with a c-myc cDNA
probe. Results shown in Figure 3 show only the expected
single band at 12.5 kb (Taub et al., 1982; Dalla Favera et al.,
1983) which is of equal intensity between the tumour sample
and the normal mucosa. No amplification is therefore pre-
sent. Furthermore no rearrangement of the c-myc gene was
found at this level of resolution in any of the ten samples.
Gene rearrangements
The Southern analysis in Figure 3 shows that of the ten
samples analysed no detectable rearrangements were found.
For this reason a larger number of samples was examined. A
further 32 samples were digested with the restriction
endonuclease EcoRl (in this case only DNA from the
tumour was examined) and the DNA separated by agarose
gel electrophoresis. The final sample composition was 11
Dukes' A tumours, 13 Dukes' B tumours, five Dukes' C
tumours and 13 Dukes' D tumours. After Southern transfer,
rearrangements of the c-myc proto-oncogene were analysed
by hybridisation with a c-myc cDNA probe. Representative
results are shown in Figure 4. As can be seen at this level of
resolution no gross rearrangement was found in any of the
samples analysed.
Discussion
patients had increased levels of c-myc in the main tumour
analysed here. One of these patients with synchronous
cancers also had synchronous polyps and expressed c-myc at
moderate levels in the main tumour (9-fold over-expression).
Gene amplification
A total of 50 colon carcinomas were examined for
amplification of the c-myc cellular proto-oncogene by dot
blot hybridisation. Of the 50 samples, 12 were Dukes' A, 17
were Dukes' stage B, eight were Dukes' stage C and 13 were
Dukes' stage D. No tumour was found to contain amplified
c-myc, as compared against hybridisation ofP-actin, c-Ki-ras
exon 1 and carboxypeptidase H (Manser et al., 1990), a gene
known to be present as a single copy in the human genome
(DRS, unpublished data), see Figure 2 for representative dot
blots. In confirmation of the dot blot analysis, no amp-
lification could be discerned in ten samples analysed by
genomic Southern blotting. In this case, 10 ytg of DNA from
The c-myc proto-oncogene is the cellular homologue of the
v-myc oncogene of avian myelocytomatosis virus (Venstrom
et al., 1982; Dalla Favera, 1982b; Watt et al., 1983a,b) and is
a member of the myc family of oncogenes, which contains
five other members besides c-myc; namely N-myc, Lmyc,
Rmyc, Pmyc and Bmyc (De Pinho et al., 1987; Ingvarsson et
al., 1988). The c-myc proto-oncogene is present as a single
copy gene in the normal human genome and has been
localised to chromosome 8 (specifically at 8q24) (Taub et al.,
1982; Dalla Favera et al., 1982a; Neel et al., 1982), and
consists of one non-coding exon and two coding exons
separated by two introns (Hamelyn & Rabbitts, 1983; Watt
et al., 1983a,b; De Pinho et al., 1987).
We have examined the expression of c-myc in colorectal
tumours. We have found that 66% of colorectal tumours
show some degree of over-expression of c-myc RNA. The
samples analysed were representative of the stages ofcolorec-
tal tumour as determined by histopathologic analysis. The
tumour samples analysed consisted of 25 Dukes' A tumours,
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Figure 1 Representative Northern blot analysis of 21 carcinomas (T) and their corresponding normal mucosa (M) hybridised
initially with c-myc cDNA and then P-actin and shown as a composite. The number above each pair (T,M) corresponds to a
patient.410 D.R. SMITH et al.
o cc CN X X X c
1D
m RI
et X qt LO
c-myc
CPH
c-Ki-ras
1-actin
o o cX ° '- CO CI: I- 'V I LID coco( co cc) c ct co CD co c co c co
Figure 2 Representative dot blot hybridisation of DNA from 16
tumour samples. Each dot contains 10#g of DNA and filter was
hybridised sequentially with probes for c-myc, carboxypeptidase
H, c-Ki-ras and P-actin. Numbers correspond to patients.
25 Dukes' B tumours, 25 Dukes' C and 25 Dukes' D
tumours. The degree of over-expression does not correlate
with either stage of the tumour as is shown in Table II
(although in agreement with other workers (Finley et al.,
1989) there is perhaps a slight reduction of the percentage of
late state tumours over-expressing c-myc i.e. Dukes' stage C
and D tumours, although as with Finley et al., this reduction
is not statistically significant), or with the age or sex of the
donor (Table IV and V respectively). The degree of over-
expression ranges from 5-fold to in excess of 400-fold over-
expression, but again this does not correlate with the stage of
the tumour (Table III).
Rothberg et al. (1985), found a significant correlation
between the site of the tumour and the over-expression of
c-myc in a study on 38 colorectal tumours. In their study
they find that 81% of left side tumours (those of the rectum,
splenic fixture, sigmoid colon and descending colon) over-
express c-myc, whereas only 36% of right side tumours
(those of the caecum, hepatic flexure, ascending colon and
transverse colon) show elevated levels ofc-myc expression (or
alternatively 85% of elevated c-myc expression is found in
left side tumours, whereas only 15% of elevated expression is
found in right side tumours). In our study, however, we find
that an almost identical proportion of left and right side
tumours over-express c-myc, i.e. 65% and 60% respectively,
although it should be noted that 80% of the tumours in our
sample cohort are left side tumours, whereas only 15% of the
tumours are right side tumours (five tumours are not
included in this analysis as the donors had multiple colorectal
tumours). Nevertheless our sample size is more than 2.5
times the size of that used in the study by Rothberg et al.
A significant correlation was found in our study between
c-myc being over-expressed in the tumour and the presence of
synchronous polyps elsewhere in the colon (Table VII).
Synchronous polyps were found in 24 of the patients.
Twenty-two of these cases occurred in patients with c-myc
over-expression in the tumour, whereas only two of the cases
of synchronous polyps were found in those patients whose
tumours did not over-express c-myc. This correlation is
statistically significant (P<0.01). Furthermore the fact that
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Figure 3 Representative Southern hybridisation analysis of c-myc in seven carcinomas (T) and compared with their corresponding
normal mucosa (M). Each lane consists of 10,ug of DNA digested with EcoRl. The 12.5 Kb c-myc band is indicated. Band size is
estimated against . DNA digested with HindIII (Lane MA) and sized as shown. The number above each pair of lanes corresponds
to the patient number.c-myc EXPRESSION IN COLORECTAL CARCINOMAS 411
w (m O m " J r- QCN'- a w) q 0 ~~co4 XV O r N m m cn LO o1 w MAN nc >N. w- X- X- q-c N C^ D o D CD N.X
94..~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~.....
43.1.m
4.3c-my
2.0-
Figure 4 Representative Southern analysis of c-myc gene rearrangement in 20 carcinoma samples. Numbers above lanes
correspond to patient numbers. Each lane contains approximately 10jig of DNA digested with EcoRl. Indicated is the 12.5 Kb
c-myc product as compared with A DNA digested with HindIII (Lane MA, size of bands shown).
5% of the patients in this study showed synchronous cancers
and that 80% of these patients showed c-myc over-expression
in the main tumour, might indicate that c-myc changes are
more widespread throughout the colon than has been found
with other oncogenes and tumour suppressor genes such as
c-Ki-ras and p53, whose changes tend to be localised to the
site of the tumour. It is possible to speculate therefore that a
wide spread colonic alteration could be genetically predeter-
mined. This supposition can be partially supported by the
wide range of basal levels of c-myc messenger RNA noted by
ourselves (data not shown) and others (Finley et al., 1989).
Amplification and rearrangement of the c-myc cellular
proto-oncogene has been shown to be associated with several
different malignancies (Yokota et al., 1986; Little et al., 1983;
Ocadiz et al., 1987; Asker et al., 1988; Alitalo et al., 1983;
Kozbar & Croce, 1984; Collins & Groudine, 1982; McCarthy
et al., 1984; Dalla Favera et al., 1982c; Lu et al., 1988;
Rothberg et al., 1984; Nakasato et al., 1984; Heerdt et al.,
1991). However, we have examined 50 colorectal tumours of
different stages and find no evidence of gene amplification.
Furthermore, examination of some 42 tumours by genomic
Southern analysis shows no evidence of gene rearrangements.
The lack of amplification or rearrangement of the c-myc gene
in colorectal carcinomas clearly indicate that a different
mechanism of activation is occurring in these tumours as
opposed to tumours of the lymphatic system such as Bur-
kitt's lymphoma, and tumours derived from uterine cervix
(Ocadiz et al., 1987), esophageal cancers (Lu et al., 1988),
hematopoietic malignancies (Rothberg et al., 1984) and
stomach cancers (Nakasato et al., 1984), where amplification
and/or rearrangement have been shown to be correlated with
tumorigenesis in primary biopsy samples.
Hence, in colorectal cancers as activation of c-myc is not a
result of either amplification or rearrangement then activa-
tion could result from either point mutations in the c-myc
gene, either in the promoter region or within the first exon as
has been shown for some other malignancies, or possibly by
the activation or deactivation of a trans-activating factor.
This latter possibility is supported by studies that show that
c-myc over-expression is correlated with loss of chromosome
5 alleles (Erisman et al., 1989). Furthermore the introduction
of chromosome 5 by microcell fusion into colon carcinoma
cell lines leads to the suppression of c-myc deregulation
(Rodriguez-Alfageme et al., 1992), possibly by the reintro-
duction of a functional APC gene, a gene that is implicated
in the genesis of spontaneous colorectal cancers and highly
implicated in the familial adenomatous polyposis syndrome,
an inherited susceptibility to colon cancer and which is
known to reside on chromosome 5 (Groden et al., 1991;
Joslyn et al., 1991).
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